Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at SNO/ASCO CNS Cancer Conference Investor Brand Network - Fri Jul 26, 9:19AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Exec to Present at Virtual Investor Closing Bell Series Investor Brand Network - Wed Jul 17, 10:33AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Enters Securities Purchase Agreements Worth Estimated $1.98M Investor Brand Network - Mon Jul 8, 10:16AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Pricing of Registered Direct, Concurrent Private Placement Investor Brand Network - Fri Jun 28, 10:40AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals(NASDAQ: CNSP) Enters in Purchase Agreements, Announces Pricing Investor Brand Network - Mon Jun 17, 10:28AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Reverse Stock Split Investor Brand Network - Tue Jun 4, 10:00AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase Investor Brand Network - Tue May 21, 9:06AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report Investor Brand Network - Fri May 17, 10:57AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024 Investor Brand Network - Wed Apr 24, 9:40AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced...

CNSP : 1.0700 (-5.31%)
CNS Pharmaceuticals (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event Investor Brand Network - Tue Apr 23, 10:04AM CDT

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured...

CNSP : 1.0700 (-5.31%)

Barchart Exclusives

3 High Dividend Stocks Beginning To Breakout Off Their 52-Week Lows Barchart - Fri Jul 26, 6:00PM CDT
These stocks have recently hit their 52-week lows and are highly rated. Is now the time to buy? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot